The Metabolization Profile of the CYP2D6 Gene in Amerindian Populations: A Review

Abstract

Background: the CYP2D6 gene is clinically important and is known to have a number of variants. This gene has four distinct metabolization profiles that are determined by the different allelic forms present in the individual. The relative frequency of these profiles varies considerably among human populations around the world. Populations from more isolated regions, such as Native Americans, are still relatively poorly studied, however. Even so, recent advances in genotyping techniques and increasing interest in the study of these populations has led to a progressive increase in publication rates. Given this, the review presented here compiled the principal papers published on the CYP2D6 gene in Amerindian populations to determine the metabolic profile of this group. Methods: a systematic literature review was conducted in three scientific publication platforms (Google Scholar, Science Direct, and Pubmed). The search was run using the keywords “CYP2D6 Amerindians” and “CYP2D6 native Americans”. Results: a total of 13 original papers met the inclusion criteria established for this study. All the papers presented frequencies of the different CYP2D6 alleles in Amerindian populations. Seven of the papers focused specifically on Amerindian populations from Mexico, while the others included populations from Argentina, Chile, Costa Rica, Mexico, Paraguay, Peru, and the United States. The results of the papers reviewed here showed that the extensive metabolization profile was the most prevalent in all Amerindian populations studied to date, followed by the intermediate, slow, and ultra-rapid, in that order. Conclusion: the metabolization profiles of the Amerindian populations reviewed in the present study do not diverge in any major way from those of other populations from around the world. Given the paucity of the data available on Amerindian populations, further research is required to better characterize the metabolization profile of these populations to ensure the development of adequate therapeutic strategies.

ACE2 polymorphisms as potential players in COVID-19 outcome

“…The Brazilian population is one of the populations with the broadest genetic diversity in the world due to the high degree of miscegenation in its formation [26][27][28]. Different regions of Brazil have significant genetic variations in the contribution of their ancestry.…”

Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax

“…(A) Predicted incidence of P. vivax in 2017 [incidence in cases per 1,000 people per year are shown on a spectrum of white (zero incidence) to dark grey (1 case per 1,000) and then blue to red (>1 case per 1,000 to >600 cases per 1,000)] (Battle et al, 2019). (B) Map of the median predicted allele frequency of G6PDd (Howes et al, 2012), and CYP2D6 metabolizer status by country and/or ethnicity (selected sample represented) (Dodgen et al, 2016;Leitão et al, 2020;Spring et al, 2020;Koopmans et al, 2021;Mehlotra et al, 2021). Maps used with permission from the Malaria Atlas Project (https://malariaatlas.org).…”

Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations

“…Genetics is one of the main factors that determine the inter-ethnic variability in the pharmacological response, and this is explained by the differences in the population frequencies of genetic polymorphisms, which have clinical implications, therefore, the doses of a drug for a certain population, are not necessarily applicable to other populations or ethnic groups (Bertilsson, 1995); this polymorphism lies in the genes that encode various enzymes and among them, the family of the cytochrome P450 system, being the isoenzyme CYP2D6 (Debrisoquine 4-hydroxylase), the most representative in liver tissue (6% of all CYP450: CYP3A4, CYP2C9, and others) (Leitão et al 2020;Saravia et al 2021), and is involved in the phase I metabolism of almost 25% of clinically important drugs (Zanger and Schwab 2013;Ray et al 2019;Jessurun et al 2020) and in the metabolism of carcinogens (Bradford 2002;Da Silva et al 2009).…”